Overexpression of CD46 protected the cancer cells from both CDC and ADCC, suggesting that the EGFR-targeted anticancer agent cetuximab downregulated the expression of CD46 to maximize the cell-killing activity, thereby affecting both CDC and ADCC. This evidence concerns the gene EGFR and cancer.